Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy

NCT ID: NCT03761160

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-16

Study Completion Date

2020-07-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits. The first phase of the research study seeks to evaluate the experience of the first version of the mobile health app within a group of participants and what they think of it.

The investigators are interested in how individuals react to the use of a developed mobile health app and what they think of it.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mobile Health App

The developed mobile health app will include the following facets:

* Physical activities
* Dietary regimen.
* The physical activities facet will encourage patients to engage in physical activities, with daily prompts, encouragement, and tips.
* Users will be asked to record the type of physical activity they engaged in during the week, and for how long.
* The dietary aspect will ask patients to log what they ate during the day and to rate how 'healthy' it is

Group Type EXPERIMENTAL

Mobile Health App

Intervention Type OTHER

mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit

Usual Care

Usual care per hospital guideline

Group Type ACTIVE_COMPARATOR

Usual care

Intervention Type OTHER

Usual care per hospital guidelines

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mobile Health App

mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit

Intervention Type OTHER

Usual care

Usual care per hospital guidelines

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Phase 1

* All recruited participants must have owned a smartphone for \>1 year
* English-speaking.
* Patients with prostate cancer aged between 40-75 years will be considered.
* No specific timeframe after prostate cancer diagnosis will be required for these patients.
* No limitations regarding their disease characteristics will be imposed (e.g. metastatic disease).
* Patients may or may not be currently receiving treatment Staff members will be recruited from
* Dana-Farber Cancer Institute Department of Medical Oncology,
* Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75 years old will be considered. Phase 2
* Men diagnosed with prostate cancer presenting to DF/BWHCC
* About to initiate ADT for the first time will be considered.
* Age range 40-75-years
* The ability to walk 400 m
* Medical clearance from their primary physician
* English speaking
* Cognitively alert
* Literate
* Ability to read or hear with or without contacts/glass and hearing aid
* Ownership of a smartphone for \>1yr

Exclusion Criteria

* Men who have been under a rigorous structured exercise regime, such as individuals who engage in more than 900 minutes of moderate physical activity per week in the last 6 months will not be considered
* Post-ADT treatment
* Planned systemic chemotherapy
* Planned treatment with abiraterone or enzalutamide
* Bone metastases
* Acute illness
* Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put them at risk from exercising
* Subordinates to the PI
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Prostate Cancer Foundation

OTHER

Sponsor Role collaborator

Dana-Farber Cancer Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Quoc-Dien Trinh, MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

QUOC-DIEN TRINH, MD

Role: PRINCIPAL_INVESTIGATOR

Brigham and Women's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brigham and Women's Hospital

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-692

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.